AtlasVector
Launch AtlasVector →
CRDL1.19-0.04 (-3.25%) session● PRIOR SESSION CLOSE
AtlasVector › Decision Feed › CRDL

CRDLcited research thesis

CRDL — what changed and why it matters

House verdict · CRDL · multi-desk debate + self-falsification

No sealed verdict on CRDL yet

No debate has been run on CRDL; debates rotate through a watchlist. The conviction call below is the signal engine’s output — one input to a debate, not a multi-desk verdict. Sealed debates on other names, each with its falsification check, are available.
Open the Glass Box →
Individual · $49 a monthThe conviction call on CRDL — outside the public coverage list

Covered names include the conviction call in the sealed record at no charge. CRDL is outside public coverage; running the signal engine on it requires a seat. The panels above do not depend on it.

Start checkout →
0 of 8 figures below re-derived from a sourcewritten 2026-10-07

This thesis is 5 days old. Statements below are as of 2026-10-07.

CRDL — what moved and why today

Context (knowledge graph)

AtlasVector tracks 0 related entities for CRDL in its knowledge graph. [c1]

What changed

  • HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
  • Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
  • Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
Key takeaways
  • HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
  • Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
  • Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
Headlines · CRDL UNAVAILABLE

The headline tape could not be read, so no articles are shown. Nothing is written in their place.

Provenance

verdicts, debates and hash-chained audit seals recorded against CRDL
Instruments 1
  • CRDL2026-10-07
Session bars 5
  • CRDL · Wed Oct 07 session barCRDL2026-10-07
  • CRDL · Tue Oct 06 session barCRDL2026-10-06
  • CRDL · Mon Oct 05 session barCRDL2026-10-05
  • CRDL · Fri Oct 02 session barCRDL2026-10-02
  • CRDL · Thu Oct 01 session barCRDL2026-10-01
Screen metrics 1
  • CRDL · screen metrics · Wed Oct 07CRDL2026-10-07

7 recorded entities · 6 links. synthetic = the row is flagged as built on synthetic inputs; no provenance = the store holds no synthetic flag for the row. Unmarked rows are flagged non-synthetic. Chain seals list sequence number, event key and SHA-256 chain hash. Verify seal opens the verdict's proof panel, where the sealed record is re-hashed in the browser and compared against the seal.

Cited sources · 5

[c1]AtlasVector knowledge graphgraph context for CRDL
[c2]NewswireHC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
[c3]NewswireCardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
[c4]NewswireCardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis
[c5]AtlasVector valuation spineconsensus valuation

The full record is in AtlasVector.

Standing monitors, multi-desk debate, audited paper trading and a persistent research record.

Open AtlasVector →